p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

Although PS-341 (bortezomib) is a promising agent to improve multiple myeloma (MM) patient outcome, 65% of patients with relapsed and refractory disease do not respond. We have previously shown that heat shock protein (Hsp)27 is upregulated after PS-341 treatment, that overexpression of Hsp27 confer...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncogene 2004-11, Vol.23 (54), p.8766-8776
Hauptverfasser:	Hideshima, Teru, Podar, Klaus, Chauhan, Dharminder, Ishitsuka, Kenji, Mitsiades, Constantine, Tai, Yu-Tzu, Hamasaki, Makoto, Raje, Noopur, Hideshima, Hiromasa, Schreiner, George, Nguyen, Aaron N, Navas, Tony, Munshi, Nikhil C, Richardson, Paul G, Higgins, Linda S, Anderson, Kenneth C
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Apoptosis Biological and medical sciences Bone marrow Boronic Acids - pharmacology Bortezomib Caspase-8 Cell Biology Cell growth Cell Line, Tumor Cell physiology Cell transformation and carcinogenesis. Action of oncogenes and antioncogenes Clinical outcomes Clinical trials Cyclin-dependent kinase inhibitor p21 Cytotoxicity Down-Regulation Drug resistance Fundamental and applied biological sciences. Psychology Heat shock proteins Heat-Shock Proteins - metabolism Hematologic and hematopoietic diseases Hsp27 protein Human Genetics Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Inhibitor drugs Internal Medicine Kinases Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis MAP kinase Medical sciences Medicine Medicine & Public Health Molecular and cellular biology Multiple myeloma Multiple Myeloma - pathology Oncology original-paper p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors Patients Phosphorylation Protein expression Protein kinase Proteins Pyrazines - pharmacology Ribose Targeted cancer therapy Transcription factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!